Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $22.2 million.

  • Abeona Therapeutics' Total Current Liabilities rose 2039.95% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 2039.95%. This contributed to the annual value of $16.6 million for FY2024, which is 2358.07% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Total Current Liabilities stood at $22.2 million, which was up 2039.95% from $34.5 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Total Current Liabilities ranged from a high of $41.9 million in Q2 2021 and a low of $7.4 million during Q1 2023
  • For the 5-year period, Abeona Therapeutics' Total Current Liabilities averaged around $18.4 million, with its median value being $16.6 million (2024).
  • In the last 5 years, Abeona Therapeutics' Total Current Liabilities crashed by 6979.11% in 2022 and then skyrocketed by 11899.67% in 2024.
  • Over the past 5 years, Abeona Therapeutics' Total Current Liabilities (Quarter) stood at $16.6 million in 2021, then plummeted by 53.2% to $7.8 million in 2022, then skyrocketed by 72.54% to $13.4 million in 2023, then rose by 23.58% to $16.6 million in 2024, then surged by 33.72% to $22.2 million in 2025.
  • Its last three reported values are $22.2 million in Q3 2025, $34.5 million for Q2 2025, and $18.0 million during Q1 2025.